- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07801612
A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis
This is a Phase I, multicenter, randomized, double-blind, placebo-controlled study evaluating HXN5003 in healthy participants and patients with moderate-to-severe atopic dermatitis (AD).
The study consists of two parts: Part A (single ascending dose in healthy participants) and Part B (multiple ascending dose in AD patients).
The primary objectives are to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary efficacy of HXN5003.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Tong Gang
- Telefonnummer: (86)13918569690
- E-post: tonggang@helixon.com
Studieorter
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kina, 310006
- Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University
-
Kontakt:
- Liming Wu
- Telefonnummer: 13750837205
- E-post: 18957118053@163.com
-
Kontakt:
- Ying Wang
- Telefonnummer: (86)-18367124548
- E-post: nancywangying@163.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Participants must be able to understand and comply with the study requirements and voluntarily sign the informed consent form (ICF).
- (Healthy Participants) Male or female participants aged 18 to 50 years (inclusive) at the time of signing the ICF.
- (Healthy Participants) Male participants weighing ≥ 50.0 kg and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 26.0 kg/m² (inclusive).
- (Patients with AD) Male or female participants aged 18 to 70 years (inclusive)
- (Patients with AD) Participants must have documented AD history, moderate-to-severe disease, and inadequate response to topical therapy at screening.
Exclusion Criteria:
- Presence of any clinically significant disease at randomization, as judged by the investigator.
- History of severe drug allergy or systemic anaphylactic reactions, such as anaphylactic shock, laryngeal edema, etc.
- Known or suspected history of immunosuppression, or history of invasive opportunistic infections, including infections that are unusually frequent, recurrent, or prolonged in duration as judged by the investigator, even after resolution of the infection.
- Participants who have resided long-term in regions with high prevalence of Human Herpesvirus-8 (HHV-8), such as Africa or the Mediterranean coastal areas.
- History of malignancy or malignant disease, with the exception of surgically excised cutaneous squamous cell carcinoma in situ, basal cell carcinoma, and cervical carcinoma in situ that have been in complete remission for more than 5 years without any evidence of recurrence.
- Female participants who are breastfeeding or pregnant, or women of childbearing potential with a positive serum pregnancy test result at screening.
- Participants with a chronic active infection or a condition that would seriously interfere with study drug administration at baseline within 4 weeks prior to randomization; or a superficial skin infection requiring treatment within 1 week prior to randomization; or an acute illness within 48 hours prior to randomization.
- (Patients with AD) Other than AD, A history of clinically significant disease which is poorly controlled or could pose a safety risk to the participant or confound the safety assessment, as judged by the Investigator to compromise participant safety in the study.
- (Patients with AD) Positive results in any of the following infectious disease screening tests: 1)History of active tuberculosis, or positive result at screening (T-SPOT.TB or QuantiFERON-TB Gold); 2)Positive for hepatitis B; 3)Positive hepatitis C antibody; 4)Positive Treponema pallidum antibody; 5)History of HIV infection, or positive HIV antibody.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Trippel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A Single Ascending Dose (SAD)
Healthy participants will receive a single subcutaneous dose of HXN5003
|
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of HXN5003.
AD participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of HXN5003.
|
|
Placebo-jämförare: Part A Placebo (SAD)
Healthy participants will receive a single subcutaneous dose of placebo
|
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of placebo.
AD Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of placebo.
|
|
Experimentell: Part B Multiple Ascending Dose (MAD)
AD participants will receive multiple subcutaneous doses of HXN5003
|
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of HXN5003.
AD participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of HXN5003.
|
|
Placebo-jämförare: Part B Placebo (MAD)
AD participants will receive multiple subcutaneous doses of placebo
|
Healthy participants will be enrolled sequentially into one of four ascending dose cohorts and will receive a single subcutaneous dose of placebo.
AD Participants will be enrolled sequentially into one of two ascending dose cohorts and will receive multiple subcutaneous doses of placebo.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part A Adverse events
Tidsram: Up to day 197
|
Incidence, severity, and causal relationship of Adverse Events (AEs)
|
Up to day 197
|
|
Part B Adverse Events
Tidsram: Up to day 281
|
Incidence, severity, and causal relationship of Adverse Events (AEs)
|
Up to day 281
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- HXN5003-A1-102
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .